Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07581834 Tamoxifen Citrate Early Stage Breast Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07581834 clinical trial report covering Tamoxifen Citrate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07581912 Cetuximab KRAS G12C mutation Solid Tumors Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07581912 clinical trial report covering Cetuximab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07579936 Recombinant Teriparatide (Salubris) Osteoporosis, Postmenopausal Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07579936 clinical trial report covering Recombinant Teriparatide (Salubris), Phase 2, endpoints, sponsor, geography, readout timing and development white s
Latest Hotspot
8 min read
NCT07579598 Sacituzumab tirumotecan Salivary gland carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07579598 clinical trial report covering Sacituzumab tirumotecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07580716 Leukocyte cell therapy (Enlivex Therapeutics) Osteoarthritis, Knee Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07580716 clinical trial report covering Leukocyte cell therapy (Enlivex Therapeutics), Phase 2, endpoints, sponsor, geography, readout timing and developme
Latest Hotspot
8 min read
NCT07582133 HRS-5965 Glomerulonephritis, IGA Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07582133 clinical trial report covering HRS-5965, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600124441 Tremelimumab Neoplasm Metastasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
ChiCTR2600124441 clinical trial report covering Tremelimumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07579884 RP-902 Alzheimer Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07579884 clinical trial report covering RP-902, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07579429 Nicotinamide riboside CCUS Clonal Cytopenia of Undetermined Significance Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07579429 clinical trial report covering Nicotinamide riboside, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07581795 Trastuzumab Advanced HER2-Positive Breast Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07581795 clinical trial report covering Trastuzumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07579949 SNH-119014 Non-transfusion dependent thalassaemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07579949 clinical trial report covering SNH-119014, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07579962 Bleomycin Sulfate Vascular Malformations Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07579962 clinical trial report covering Bleomycin Sulfate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.